IBT B Share Price Performance
SEK 60.10
23.30 (63.32%)
Price SEK 60.10
Share PriceSEK 60.10
Companies Like Infant Bacterial Therapeutics (STO:IBT B) Are In A Position To Invest In Growth
Aug 28
Infant Bacterial Therapeutics AB (publ) Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
IBT B Community Narratives
There are no narratives available yet.
There are no community narratives available.
Snowflake Analysis
Infant Bacterial Therapeutics AB (publ) Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 13, 2025
- -7.60
- 100.00%
- 10,232,700.00%
- 0%
About IBT B
- Founded
- 2011
- Employees
- 8
- CEO
- WebsiteView website
Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is in Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants. In addition, its drug candidates include IBP-1118 to prevent retinopathy of prematurity that causes blindness in premature babies; and IBP-1122, indicated to eliminate vancomycin resistant enterococci that cause antibiotic resistant hospital infections. The company was incorporated in 2011 and is based in Stockholm, Sweden.
